Key result
Comprehensive genomic profiling identifies multiple actionable mutations and chromosomal alterations in primary cardiac lymphoma.
Why the study?
The clinical and pathologic characteristics of primary cardiac diffuse large B cell lymphoma remain unclear, especially in Eastern countries, and its genomic alterations had not been studied previously.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
This case report provides the first comprehensive whole-exome and SNP array genomic characterization of primary cardiac diffuse large B-cell lymphoma, identifying actionable MCD-subtype mutations (MYD88 and CD79B) that may guide targeted therapy.
Primary cardiac diffuse large B cell lymphoma (PC-DLBCL) is a rare kind of hematological malignancy, and its clinical and pathologic characteristics, especially in Eastern countries, remain unclear. Moreover, genomic alterations in PC-DLBCL have not been studied previously. We describe a case of a 57-year-old man who presented with exertional dyspnoea due to a heart mass in April 2018 and was diagnosed with PC-DLBCL characterized by immunohistochemical markers of the activated B cell (ABC) subtype and double expression of c-MYC and Bcl-2. Mutations in a total of 11 genes— TBL1XR1, CD79B, IGLL5, ZMYM3, MYD88, TMSB4X, PIM1, BTK, NRXN3, CUX1 , and CSMD1 —were detected via next-generation sequencing (NGS), while 19 copy number variations (CNVs) such as 1q+, 3p+, 3q+(*2), 5p+, 6p−, 6q−, 7q+, +11, 12q−, 15q−, 17q+, 17p−, +18, 19q+, 19p−, 19q−, X q+, and −Y and 4 copy-neutral loss of heterozygosity (CN-LOH) lesions located at 1q21.1q44, 3p26.3q11.2, 3q13.11q29 and 6p22.2p21.32 were identified by single nucleotide polymorphism (SNP) array karyotyping. Some key gene alterations in lymphoma, such as PRDM1 deletion and Bcl-2 amplification, were identified using SNP array analysis. The patient received 6 courses of chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, R-CHOP regimen) after surgery and is currently in remission. In summary, the present case was diagnosed as PC-DLBCL, ABC subtype by the Hans algorithm and double expression lymphoma, with co-occurrence of the MYD88L265P and CD79B mutations (MCD) subtype by genetic alteration analysis. This study presents a unique PC-DLBCL case in which complex genomic alterations were revealed by NGS and SNP array analysis, which has never been reported in the literature, and these findings could provide new insight into the genomic characterization of PC-DLBCL.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2019) conducted a case report in Primary cardiac diffuse large B cell lymphoma (PC-DLBCL) (n=1). Surgical resection and 6 courses of R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) plus genomic profiling (NGS and SNP array) was evaluated on Genomic alterations characterization and clinical remission. Next-generation sequencing and SNP array analysis in a patient with primary cardiac diffuse large B cell lymphoma identified 13 point mutations across 11 genes, 19 copy number variations, and 4 copy-neutral loss of heterozygosity lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: